PRESS RELEASE
12th Meeting of the Committee for Orphan Medicinal Products

The Committee for Orphan Medicinal Products (COMP) held its twelfth meeting on 9-10 April 2001.

Six positive opinions on the designation of orphan medicinal products, were adopted by the Committee, for the following conditions:
- Emphysema secondary to congenital alpha-1-antitrypsin deficiency
- Methanol poisoning
- Ovarian cancer
- Scarring in glaucoma filtration surgical procedures
- Severe Combined Immunodeficiency (SCID) X1 Disease
- Soft tissue sarcoma

These opinions, will now be forwarded to the European Commission for the decision making process.

One oral explanation took place during the meeting and two applications for orphan medicinal product designation were withdrawn by the sponsors. Eight decisions on orphan designation were granted by the European Commission1 in March 2001, see Annex I.

The status of orphan designation procedures, as of 10 April 2001, is summarised in the table below:

<table>
<thead>
<tr>
<th>Year</th>
<th>Intent to file Notified</th>
<th>Applications submitted</th>
<th>Applications withdrawn</th>
<th>Positive COMP Opinions</th>
<th>Negative COMP Opinions</th>
<th>Designations granted by Commission</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>31</td>
<td>72</td>
<td>3</td>
<td>26</td>
<td>-</td>
<td>14</td>
</tr>
<tr>
<td>2001</td>
<td>17</td>
<td>14</td>
<td>8</td>
<td>17</td>
<td>3</td>
<td>20</td>
</tr>
<tr>
<td>Total</td>
<td>48</td>
<td>86</td>
<td>11</td>
<td>43</td>
<td>3</td>
<td>34</td>
</tr>
</tbody>
</table>

The Committee appointed coordinators and experts for a number of upcoming applications.

The 1st EMEA Workshop with the Pharmaceutical Industry on Orphan Medicinal Products was held on 11 April 2001. Members of the COMP, the European Commission and the EMEA met with fifty representatives of the pharmaceutical industry. The European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Association for Bioindustries (EuropaBio), the Emerging Biopharmaceutical Enterprises (EBE) and sponsors of products which have been subject of positive opinions were represented. The Committee’s achievements to date were discussed as well as proposals for improving transparency. A Press Release from this Workshop (COMP/141/01) will be published on the EMEA’s website.

The next COMP meeting will be held on 22-23 May 2001.

NOTE: This Press Release, together with other information about the work of the EMEA, may be found on the internet at the following location: http://www.emea.eu.int/

Contacts for further information:
Scientific Advice and Orphan Drugs Sector, Pre-Authorisation Human Medicines Unit
Dr. Patrick Le Courtois
Tel. (44-20) 74 18 86 49

or
Ms. Melanie Carr
Tel. (44-20) 74 18 85 75

1 Details of all orphan designations granted to date by the European Commission are entered in the Community Register of Orphan Medicinal Products (http://pharmacos.eudra.org/register/orphreg.htm)
### Medicinal products Designated as Orphan Medicinal Products in March 2001

<table>
<thead>
<tr>
<th>Active substance</th>
<th>Ibuprofen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor</strong></td>
<td>Orphan Europe</td>
</tr>
<tr>
<td><strong>Orphan Indication</strong></td>
<td>Prevention of patent ductus arteriosus in premature neonates of less than 34 weeks of gestational age</td>
</tr>
<tr>
<td><strong>Opinion receipt date</strong></td>
<td>19/1/01</td>
</tr>
<tr>
<td><strong>Date of Commission Decision</strong></td>
<td>5/3/01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Active substance</th>
<th>Inolimomab</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor</strong></td>
<td>OPi Orphan Pharma international</td>
</tr>
<tr>
<td><strong>Orphan Indication</strong></td>
<td>Treatment of Graft versus Host Disease</td>
</tr>
<tr>
<td><strong>Opinion receipt date</strong></td>
<td>18/1/01</td>
</tr>
<tr>
<td><strong>Date of Commission Decision</strong></td>
<td>5/3/01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Active substance</th>
<th>Ribavirin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor</strong></td>
<td>ICN Pharmaceuticals Ltd.</td>
</tr>
<tr>
<td><strong>Orphan Indication</strong></td>
<td>Treatment of adenovirus infection in immunocompromised patients</td>
</tr>
<tr>
<td><strong>Opinion receipt date</strong></td>
<td>18/1/01</td>
</tr>
<tr>
<td><strong>Date of Commission Decision</strong></td>
<td>8/3/01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Active substance</th>
<th>8-cyclopentyl-1,3-dipropylxanthine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor</strong></td>
<td>SciClone Pharmaceuticals Italy S.r.l</td>
</tr>
<tr>
<td><strong>Orphan Indication</strong></td>
<td>Treatment of cystic fibrosis</td>
</tr>
<tr>
<td><strong>Opinion receipt date</strong></td>
<td>13/2/01</td>
</tr>
<tr>
<td><strong>Date of Commission Decision</strong></td>
<td>29/3/01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Active substance</th>
<th>Arsenic trioxide</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor</strong></td>
<td>Cell Therapeutics (UK) Ltd.</td>
</tr>
<tr>
<td><strong>Orphan Indication</strong></td>
<td>Treatment of myelodysplastic syndromes</td>
</tr>
<tr>
<td><strong>Opinion receipt date</strong></td>
<td>13/2/01</td>
</tr>
<tr>
<td><strong>Date of Commission Decision</strong></td>
<td>29/3/01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Active substance</th>
<th>Arsenic trioxide</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor</strong></td>
<td>Cell Therapeutics (UK) Ltd.</td>
</tr>
<tr>
<td><strong>Orphan Indication</strong></td>
<td>Treatment of multiple myeloma</td>
</tr>
<tr>
<td><strong>Opinion receipt date</strong></td>
<td>13/2/01</td>
</tr>
<tr>
<td><strong>Date of Commission Decision</strong></td>
<td>29/3/01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Active substance</th>
<th>Ranpirnase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor</strong></td>
<td>Dr. Erika Morgenstern</td>
</tr>
<tr>
<td><strong>Orphan Indication</strong></td>
<td>Treatment of malignant mesothelioma</td>
</tr>
<tr>
<td><strong>Opinion receipt date</strong></td>
<td>13/2/01</td>
</tr>
<tr>
<td><strong>Date of Commission Decision</strong></td>
<td>29/3/01</td>
</tr>
<tr>
<td><strong>Active substance</strong></td>
<td>Gusperimus trihydrochloride</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td><strong>Sponsor</strong></td>
<td>Euro Nippon Kayaku GmbH</td>
</tr>
<tr>
<td><strong>Orphan Indication</strong></td>
<td>Treatment of Wegener’s Granulomatosis</td>
</tr>
<tr>
<td><strong>Opinion receipt date</strong></td>
<td>13/2/01</td>
</tr>
<tr>
<td><strong>Date of Commission Decision</strong></td>
<td>29/3/01</td>
</tr>
</tbody>
</table>